BioSpace News Archive

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the second and third quarters of 2022.

Albireo Pharma, Inc. announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo’s common stock.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022.

Soligenix, Inc. announced today publication of preclinical immunogenicity challenge studies for RiVax® (heat stable ricin toxin vaccine) demonstrating statistically significant correlates of protection predicting survival after lethal aerosolized ricin challenge in non-human primates (NHPs).

Venatorx Pharmaceuticals today announced two organizational changes: the retirement of its Chief Medical Officer, Timothy Henkel, M.D., Ph.D., and the step-down of Vincent Milano from the Board of Directors.

Invitae today announced that it has completed a transaction with Integrated DNA Technologies, Inc. (IDT), which includes the sale of Next Generation Sequencing (NGS) research assays under the trademarked name Archer®, also known as the Research Use Only (RUO) kitted solutions.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN).

KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc.

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes.